Anaphylaxis Treatment Market Size, Trends and Growth Analysis by 2027

The anaphylaxis treatment market is projected to grow significantly, reaching an estimated US$ 4,787.66 million by 2028, up from US$ 2,664.66 million in 2021. This growth represents a compound annual growth rate (CAGR) of 8.7% from 2021 to 2028.

Several factors are driving this market expansion, notably the increasing prevalence of anaphylaxis and the recent approvals of epinephrine products. Despite this growth potential, challenges such as limited access to epinephrine auto-injectors in low-income regions pose significant barriers to market development.

Epinephrine remains the most effective treatment for anaphylaxis. However, research indicates that its use is often suboptimal due to factors such as high costs, limited availability, and a general lack of awareness regarding both the drug and the onset of anaphylactic reactions. In response to this, various organizations are working on developing generic alternatives for anaphylaxis treatment.

For instance, in April 2020, Amphastar Pharmaceuticals announced that it had received FDA approval for its new drug application for epinephrine injection, USP 30mg/30mL (1mg/mL), which is available in multiple dose vials. This generic product is considered equivalent to Adrenalin, produced by Endo International and Par Pharmaceutical, and is indicated for emergency treatment of allergic reactions, including anaphylaxis. Nevertheless, the number of companies operating in this segment remains limited.

The demand for epinephrine has been increasing, yet the supply of products has not kept pace. According to the Pew Charitable Trusts, the demand for epinephrine auto-injectors has surged in recent years, with EpiPen prescriptions in the United States rising from approximately 2.5 million in 2011 to 3.5 million in 2015. This increase is largely driven by heightened demand from educational institutions.

Moreover, in January 2020, the U.S. Food and Drug Administration (FDA) approved Palforzia, a drug designed to treat peanut allergies. This medication is intended to reduce the risk of allergic reactions, including anaphylaxis, that may occur following accidental exposure to peanuts. The growing number of approvals for epinephrine auto-injectors is further propelling the growth of the anaphylaxis treatment market.

The market is categorized by medication type, which includes epinephrine, antihistamines, steroids, beta-agonists, and others. The epinephrine segment dominated the market in 2020 and is expected to exhibit the highest CAGR during the forecast period. The growth in this segment can be attributed to the introduction of generic epinephrine products and improved accessibility. For example, in July 2019, Sandoz, a division of Novartis AG, launched its generic pre-filled epinephrine auto-injector, Symjepi.

To compile the report on the anaphylaxis treatment market, various primary and secondary sources were utilized, including reputable organizations such as the World Health Organization (WHO), National Health Service, Centers for Disease Control and Prevention (CDC), International Study of Asthma and Allergies in Childhood, National Institute of Allergy and Infectious Diseases, and the National Asthma Education and Prevention Program, along with information from company websites.

In conclusion, the anaphylaxis treatment market is on a growth trajectory, driven by increasing incidences of anaphylaxis and the introduction of new epinephrine products. However, challenges such as accessibility in low-income areas and the need for greater awareness about anaphylaxis and its treatment options remain critical issues that need to be addressed to fully realize the market's potential.